MItochondrial Myopathies Clinical Trial
Official title:
A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Mitochondrial Myopathy (MOTOR)
Mitochondrial myopathies are a multisystemic group of disorders that are characterized by a wide range of biochemical and genetic mitochondrial defects and variable modes of inheritance. Currently there are no effective treatments for this disease. Despite the heterogeneous myopathy phenotypes, a unifying feature of mitochondrial myopathies is that the pathogenic mtDNA mutations and/or nuclear mutations of the electron transport chain invariably lead to dysfunctional mitochondrial respiration. This reduction in mitochondrial respiration leads to a reduced ability to produce cellular adenosine triphosphate (ATP), often resulting in muscle weakness, exercise intolerance, and fatigue in patients with mitochondrial myopathies. RTA 408 is a potent activator of Nrf2 and inhibitor of NF κB (nuclear factor kappa-light-chain-enhancer of activated B cells), and thus induces an antioxidant and anti-inflammatory phenotype. Several lines of evidence suggest that Nrf2 activation can increase mitochondrial respiration and biogenesis. Collectively, available data suggest that the ability of RTA 408 to activate Nrf2 and induce its target genes could potentially improve muscle function, oxidative phosphorylation, antioxidant capacity, and mitochondrial biogenesis in patients with mitochondrial myopathies. This study will be a randomized, placebo-controlled, double-blind, dose-escalation study to evaluate the safety of omaveloxolone (RTA 408) at various doses in patients with mitochondrial myopathies.
Study Sponsor, originally Reata Pharmaceuticals, Inc., is now Reata Pharmaceuticals, Inc., a wholly owned subsidiary of Biogen. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06051448 -
Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD).
|
Phase 1/Phase 2 | |
| Completed |
NCT02909400 -
The KHENERGY Study
|
Phase 2 | |
| Completed |
NCT04165239 -
The KHENERGYZE Study
|
Phase 2 | |
| Recruiting |
NCT06080568 -
Human Mitochondrial Stress-driven Obesity Resistance
|
||
| Recruiting |
NCT06080581 -
Mitochondrial Dysfunctions Driving Insulin Resistance
|
||
| Completed |
NCT05012358 -
Genomic Profiling of Mitochondrial Disease - Imaging Analysis for Precise Mitochondrial Medicine
|
||
| Recruiting |
NCT05569122 -
Applying pGz in Mitochondrial Disease
|
Phase 1 | |
| Completed |
NCT03888716 -
A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease
|
Phase 1 | |
| Completed |
NCT05063721 -
MABs Therapy m.3243A>G Mutation Carriers
|
Phase 1 | |
| Completed |
NCT03973203 -
Niacin Supplementation in Healthy Controls and Mitochondrial Myopathy Patients
|
N/A | |
| Recruiting |
NCT05200702 -
Assessment of Safety and Acute Effects of a Knee-hip Powered Soft Exoskeleton in Patients With Neuromuscular Disorders
|
N/A | |
| Recruiting |
NCT04086329 -
Validation of Oxygen Nanosensor in Mitochondrial Myopathy
|
Phase 1 | |
| Completed |
NCT03513835 -
Diagnostic Screening Tests and Potential Biomarkers in Mitochondrial Myopathies
|
||
| Completed |
NCT04538521 -
NiaMIT Continuation With Early-stage Mitochondrial Myopathy Patients
|
N/A | |
| Recruiting |
NCT05554835 -
Global Registry and Natural History Study for Mitochondrial Disorders
|
||
| Completed |
NCT03432871 -
Nicotinamide Riboside and Mitochondrial Biogenesis
|
N/A | |
| Completed |
NCT02375438 -
Nutritional Assessment in Mitochondrial Cytopathy
|
N/A | |
| Recruiting |
NCT05199740 -
mtDNA Mutation Load Analysis in Mesoangioblasts
|
||
| Recruiting |
NCT05346627 -
Home Based Personalized Training and Video Consultation in Mitochondrial Myopathies: Study of Efficacy and Tolerance.
|
N/A | |
| Recruiting |
NCT05199246 -
Assessment of Safety and Acute Effects of a Lower-limb Powered Dermoskeleton in Patients With Neuromuscular Disorders
|
N/A |